HC Wainwright Reiterates Buy Rating on BDSX
HC Wainwright maintains its Buy rating on BDSX, setting a $26 price target, a 72.64% upside from the current price.
Key Points
- HC Wainwright reiterated its Buy rating on BDSX on June 15, 2026, with a price target of $26.
- HC Wainwright's $26 price target implies 72.64% upside from Biodesix, Inc.'s ($BDSX) current $15.06 share price.
- BDSX shares are currently trading at $15.06, with insider trading activity noted in March 2026.
- Peer funds like AIGH Capital and Telemark Asset Management have adjusted their holdings in BDSX.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
HC Wainwright reiterated its Buy rating on BDSX on June 15, 2026, setting a price target of $26. This reaffirmation suggests continued confidence in the company's prospects. Shares of BDSX are currently trading at $15.06.
Other Institutional Activity in BDSX
Several institutional investors have recently adjusted their positions in BDSX. AIGH Capital Management LLC initiated a position with 758,328 shares, valued at approximately $10.99 million. Telemark Asset Management, LLC increased its holdings by 162,000 shares to a total of 489,824 shares, worth about $7.10 million. Aberdeen Group PLC also grew its stake by 196,013 shares, reaching 458,438 shares valued at roughly $6.65 million.
Biodesix, Inc. Stock Down 43.9%
BDSX shares are trading at $15.06. The stock has attracted attention from investors, partly due to its recent analyst ratings and institutional activity. The market is watching closely to see if BDSX can reach the price targets set by analysts.
$BDSX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Biodesix, Inc.
Insider trading activity at BDSX included several sales on February 23, 2026. Robin Harper Cowie, the CFO, Secretary, and Treasurer, sold 535 shares at an average price of $12.78. Chris Vazquez, the Chief Accounting Officer, sold 211 shares at the same price. Additionally, Chief Commercial Officer Kieran O'Kane and President & CEO Scott Hutton sold 535 and 1,490 shares, respectively.
Analysts Set New Price Targets
On June 15, 2026, HC Wainwright reiterated its Buy rating on BDSX with a $26 price target. Previously, on May 5, 2026, Canaccord Genuity maintained its Buy rating with a $22 target. The consensus among analysts remains positive, with a general Buy recommendation and a mean target price reflecting optimism about BDSX's future performance.
Bottom Line
HC Wainwright's reaffirmation of its Buy rating for BDSX, with a $26 target, highlights ongoing analyst confidence. Investors are likely to keep an eye on BDSX, especially given the recent institutional and insider activities. As always, 13F filings and insider trades are backward-looking and may not reflect current positions.
Get Biodesix, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BDSX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.